Rothenbacher Dietrich, Koenig Wolfgang, Brenner Hermann
Department of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
Arch Intern Med. 2006;166(22):2455-60. doi: 10.1001/archinte.166.22.2455.
The purpose of this study was to investigate the prognostic role of N-terminal pro-B-natriuretic peptide (NT-proBNP) serum level compared with C-reactive protein (CRP) level and creatinine clearance (CrCl) for the subsequent risk of cardiovascular events in a large cohort of patients with stable coronary heart disease (CHD).
Serum concentrations of NT-proBNP and CRP and CrCl were measured at baseline in a cohort of 1051 patients aged 30 to 70 years with CHD. The Cox proportional hazards model was used to determine the prognostic value of NT-proBNP, CRP, and CrCl on a combined cardiovascular disease (CVD) end point (fatal and nonfatal myocardial infarction and stroke).
During follow-up (mean of 48.7 months), 95 patients (9.0%) experienced a secondary CVD event. Patients in the top quartile of the NT-proBNP distribution at baseline had a hazard ratio (HR) of 3.34 (95% confidence interval [CI], 1.74-6.45) for subsequent secondary CVD events compared with those in the bottom quartile (P for trend <.001) after controlling for age, sex, smoking status, history of diabetes mellitus, initial management of CHD, rehabilitation clinic, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and treatment with lipid-lowering drugs. For CRP, the corresponding HR was 1.76 (95% CI, 0.96-3.24) (P value for trend, .06). Patients with CrCl levels lower than 60 mL/min had an HR of 2.39 (95% CI, 1.06-5.40) compared with patients with a CrCl of 90 mL/min or higher (P for trend, .002). If all 3 markers were included simultaneously in 1 model, NT-proBNP still showed predictive ability for recurrent CVD events.
N-terminal proBNP may be a clinically useful marker weeks after an acute coronary event and may provide complementary prognostic information to established risk determinants.
本研究旨在探讨在一大群稳定型冠心病(CHD)患者中,与C反应蛋白(CRP)水平和肌酐清除率(CrCl)相比,N末端B型利钠肽原(NT-proBNP)血清水平对后续心血管事件风险的预后作用。
对1051例年龄在30至70岁的CHD患者队列在基线时测量NT-proBNP、CRP血清浓度和CrCl。采用Cox比例风险模型确定NT-proBNP、CRP和CrCl对复合心血管疾病(CVD)终点(致命和非致命性心肌梗死及中风)的预后价值。
在随访期间(平均48.7个月),95例患者(9.0%)发生了继发性CVD事件。在控制年龄、性别、吸烟状况、糖尿病史、CHD的初始治疗、康复诊所、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和降脂药物治疗后,基线时NT-proBNP分布处于最高四分位数的患者与最低四分位数的患者相比,后续继发性CVD事件的风险比(HR)为3.34(95%置信区间[CI],1.74 - 6.45)(趋势P值<.001)。对于CRP,相应的HR为1.76(95% CI,0.96 - 3.24)(趋势P值,.06)。CrCl水平低于60 mL/min的患者与CrCl为90 mL/min或更高的患者相比,HR为2.39(95% CI,1.06 - 5.40)(趋势P值,.002)。如果将所有3个标志物同时纳入1个模型,NT-proBNP仍显示出对复发性CVD事件的预测能力。
N末端B型利钠肽原可能是急性冠状动脉事件数周后临床上有用的标志物,并可能为既定的风险决定因素提供补充预后信息。